Combination of TATE and PD-1 Inhibitor in Liver Cancer

Key facts

Sponsor

Teclison Ltd.

Principal Investigator

Nadine Abi-Jaoudeh, MD

UC Irvine Medical Center

Intervention

Nivolumab Injectable Product(drug)

Enrollment

54 enrolled

Eligibility

18-80 years · All sexes

Timeline

2017 – 2027

Study locations (3)

• University of California, Irvine, Orange, California, United States
• University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
• Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07328009
  A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
  Fudan University
• RECRUITINGNCT07295340
  Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
  West China Hospital
• RECRUITINGPHASE1NCT07364357
  A Phase I Study of CREPT-618 in Locally Advanced HCC
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGPHASE4NCT06717919
  HOPE Against Cancer Recurrence in HCC
  Philipp Dutkowski
• RECRUITINGNCT07173868
  FDG PET-CT in Advanced Breast Cancer
  Samsung Medical Center
• RECRUITINGNANCT06899152
  HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
  Montefiore Medical Center
• RECRUITINGPHASE1, PHASE2NCT07053488
  CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
  AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
• RECRUITINGNANCT06934018
  Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
  Fudan University

See all trials for Pediatric hepatocellular carcinoma →